Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1970 2
1971 1
1972 3
1973 6
1974 2
1975 2
1976 1
1977 4
1978 6
1979 9
1980 3
1981 11
1982 9
1983 8
1984 10
1985 15
1986 16
1987 9
1988 13
1989 6
1990 6
1991 7
1992 8
1993 3
1994 6
1995 4
1996 5
1997 3
1998 8
1999 8
2000 4
2001 11
2002 9
2003 9
2004 13
2005 15
2006 22
2007 22
2008 30
2009 28
2010 23
2011 25
2012 20
2013 27
2014 22
2015 19
2016 20
2017 23
2018 16
2019 16
2020 24
2021 29
2022 23
2023 14
2024 21
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

632 results

Results by year

Filters applied: . Clear all
Page 1
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Yenerel MN, Illés A, Kay N, Garcia-Marco JA, Mato A, Pinilla-Ibarz J, Seymour JF, Lepretre S, Stilgenbauer S, Robak T, Rothbaum W, Izumi R, Hamdy A, Patel P, Higgins K, Sohoni S, Jurczak W. Byrd JC, et al. Among authors: kay n. J Clin Oncol. 2021 Nov 1;39(31):3441-3452. doi: 10.1200/JCO.21.01210. Epub 2021 Jul 26. J Clin Oncol. 2021. PMID: 34310172 Free PMC article. Clinical Trial.
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M. Shanafelt TD, et al. Among authors: kay ne. N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073. N Engl J Med. 2019. PMID: 31365801 Free PMC article. Clinical Trial.
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome.
Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broséus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ. Parry EM, et al. Among authors: kay ne. Nat Med. 2023 Jan;29(1):158-169. doi: 10.1038/s41591-022-02113-6. Epub 2023 Jan 9. Nat Med. 2023. PMID: 36624313 Free PMC article.
Defining precancer: a grand challenge for the cancer community.
Faupel-Badger J, Kohaar I, Bahl M, Chan AT, Campbell JD, Ding L, De Marzo AM, Maitra A, Merrick DT, Hawk ET, Wistuba II, Ghobrial IM, Lippman SM, Lu KH, Lawler M, Kay NE, Tlsty TD, Rebbeck TR, Srivastava S; Precancer Think Tank Team. Faupel-Badger J, et al. Among authors: kay ne. Nat Rev Cancer. 2024 Nov;24(11):792-809. doi: 10.1038/s41568-024-00744-0. Epub 2024 Oct 1. Nat Rev Cancer. 2024. PMID: 39354069 Review.
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M, Kay NE. Shanafelt TD, et al. Among authors: kay ne. Blood. 2022 Jul 14;140(2):112-120. doi: 10.1182/blood.2021014960. Blood. 2022. PMID: 35427411 Free PMC article. Clinical Trial.
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS. Sterner RM, et al. Among authors: kay ne. Blood. 2019 Feb 14;133(7):697-709. doi: 10.1182/blood-2018-10-881722. Epub 2018 Nov 21. Blood. 2019. PMID: 30463995 Free PMC article.
Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma.
Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Nevala WK, Walters DK, Parikh SA, Lin Y, Jelinek DF, Kay NE, Bergsagel PL, Kenderian SS. Sakemura R, et al. Among authors: kay ne. Blood. 2022 Jun 30;139(26):3708-3721. doi: 10.1182/blood.2021012811. Blood. 2022. PMID: 35090171 Free PMC article.
The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia.
Hägerstrand D, Oder B, Cortese D, Qu Y, Binzer-Panchal A, Österholm C, Del Peso Santos T, Rabbani L, Asl HF, Skaftason A, Ljungström V, Lundholm A, Koutroumani M, Haider Z, Jylhä C, Mollstedt J, Mansouri L, Plevova K, Agathangelidis A, Scarfò L, Armand M, Muggen AF, Kay NE, Shanafelt T, Rossi D, Orre LM, Pospisilova S, Barylyuk K, Davi F, Vesterlund M, Langerak AW, Lehtiö J, Ghia P, Stamatopoulos K, Sutton LA, Rosenquist R. Hägerstrand D, et al. Among authors: kay ne. Leukemia. 2024 Nov;38(11):2429-2442. doi: 10.1038/s41375-024-02379-4. Epub 2024 Sep 11. Leukemia. 2024. PMID: 39261602 Free PMC article.
Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms.
Nadeu F, Shuai S, Clot G, Hilton LK, Diaz-Navarro A, Martín S, Royo R, Baumann T, Kulis M, López-Oreja I, Cossio M, Lu J, Ljungström V, Young E, Plevova K, Knisbacher BA, Lin Z, Hahn CK, Bousquets P, Alcoceba M, González M, Colado E, Payer ÁR, Aymerich M, Terol MJ, Rivas-Delgado A, Enjuanes A, Ruiz-Gaspà S, Chatzikonstantinou T, Hägerstrand D, Jylhä C, Skaftason A, Mansouri L, Stranska K, Doubek M, van Gastel-Mol EJ, Davis Z, Walewska R, Scarfò L, Trentin L, Visentin A, Parikh SA, Rabe KG, Moia R, Armand M, Rossi D, Davi F, Gaidano G, Kay NE, Shanafelt TD, Ghia P, Oscier D, Langerak AW, Beà S, López-Guillermo A, Neuberg D, Wu CJ, Getz G, Pospisilova S, Stamatopoulos K, Rosenquist R, Huber W, Zenz T, Colomer D, Martín-Subero JI, Delgado J, Morin RD, Stein LD, Puente XS, Campo E. Nadeu F, et al. Among authors: kay ne. Leukemia. 2025 Sep;39(9):2076-2086. doi: 10.1038/s41375-025-02667-7. Epub 2025 Jun 30. Leukemia. 2025. PMID: 40588565 Free PMC article.
Natural killer cells.
Kay NE. Kay NE. Crit Rev Clin Lab Sci. 1986;22(4):343-59. doi: 10.3109/10408368509165790. Crit Rev Clin Lab Sci. 1986. PMID: 2419034 Review.
632 results